Topotecan
- Generic Name
- Topotecan
- Brand Names
- Hycamtin, Potactasol, Topotecan Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23N3O5
- CAS Number
- 123948-87-8
- Unique Ingredient Identifier
- 7M7YKX2N15
- Background
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
- Indication
用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。
- Associated Conditions
- Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Conditions
- GanglioneuroblastomaNeuroblastoma
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationProcedure: Biospecimen CollectionProcedure: Bone Marrow Aspiration and BiopsyProcedure: Computed TomographyProcedure: EchocardiographyRadiation: External Beam Radiation TherapyRadiation: Iobenguane I-123Radiation: Iobenguane I-131Procedure: Multigated Acquisition ScanProcedure: Positron Emission TomographyProcedure: Magnetic Resonance ImagingProcedure: Therapeutic Conventional Surgery
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 724
- Registration Number
- NCT03126916
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
- Conditions
- Neuroblastoma
- Interventions
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Target Recruit Count
- 65
- Registration Number
- NCT03107988
- Locations
- 🇬🇧
Royal Marsden Hospital, Sutton, Surrey, United Kingdom
🇺🇸Cook Children's Healthcare System, Fort Worth, Texas, United States
🇺🇸Children's Healthcare of Atlanta, Atlanta, Georgia, United States
Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 483
- Registration Number
- NCT03098030
- Locations
- 🇺🇸
Genesis Cancer Center, Hot Springs, Arkansas, United States
🇺🇸Hartford Hospital, Hartford, Connecticut, United States
🇭🇺Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház, Semmelweis Tagkórház, Tüdőgyógyászati Osztály, Miskolc, Hungary
Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 491
- Registration Number
- NCT03088813
- Locations
- 🇺🇸
Florida Cancer Specialists (South Region), Fort Myers, Florida, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸North Shore Hematology Oncology Associates, PC, East Setauket, New York, United States
Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 444
- Registration Number
- NCT03061812
- Locations
- 🇺🇸
Georgia Cancer Center /ID# 160206, Atlanta, Georgia, United States
🇺🇸Cedars-Sinai Medical Center /ID# 157102, Beverly Hills, California, United States
🇺🇸Mitchell Cancer Institute /ID# 158151, Mobile, Alabama, United States
Immunotherapy as Second-line in Patient With Small Cell Lung Cancer
- Conditions
- Small Cell Lung CancerSmall Cell Lung Cancer Extensive StageSmall Cell Lung Cancer Limited Stage
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2021-02-10
- Lead Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
- Target Recruit Count
- 73
- Registration Number
- NCT03059667
- Locations
- 🇫🇷
Mulhouse - CH, Mulhouse, France
🇫🇷Centre Antoine Lacassagne, Nice, France
🇫🇷Annemasse - CH, Ambilly, France
Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer
- First Posted Date
- 2016-12-02
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- First Hospitals affiliated to the China PLA General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT02980809
Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 9
- Registration Number
- NCT02963090
- Locations
- 🇺🇸
Metro MN Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States
🇺🇸The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients
- Conditions
- Ovarian Neoplasms
- Interventions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2021-08-25
- Target Recruit Count
- 242
- Registration Number
- NCT02903004
- Locations
- 🇮🇹
Domenica Lorusso, Rome, Italy
Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Cellid Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT02866006
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.